Evidence map›Paper›PMID 39159141›Full record

ArticlePloS one2024

Non-pharmaceutical interventions and epigenetic aging in adults: Protocol for a scoping review.

Alina Liebich, Shenglin Zheng, Theresa Schachner, Jacqueline Mair, Mia Jovanova, Falk Müller-Riemenschneider, Tobias Kowatsch

Abstract read
In one paragraph

Article in PloS one, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Alina LiebichSchool of Medicine, University of St. Gallen, St.Gallen, Switzerland.
Shenglin ZhengSaw Swee Hock School of Public Health, National University of Singapore and National University Health System, Singapore, Singapore.
Theresa SchachnerDepartment of Management, Technology, and Economics, ETH Zurich, Zurich, Switzerland.
Jacqueline MairSaw Swee Hock School of Public Health, National University of Singapore and National University Health System, Singapore, Singapore.ORCID 0000-0002-1466-8680
Mia JovanovaSchool of Medicine, University of St. Gallen, St.Gallen, Switzerland.
Falk Müller-RiemenschneiderSaw Swee Hock School of Public Health, National University of Singapore and National University Health System, Singapore, Singapore.
Tobias KowatschSchool of Medicine, University of St. Gallen, St.Gallen, Switzerland.ORCID 0000-0001-5939-4145

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionAging is the strongest risk factor for most chronic diseases. The rising burden of an aging population and non-communicable diseases (NCDs), contributes to escalating costs for society. Several non-pharmaceutical interventions can lower the risk of NCDs, including common mental disorders (CMDs), and may slow down biological aging, as evidenced by outcome markers such as epigenetic clocks. However, a comprehensive overview of whether and which non-pharmaceutical interventions may impact human epigenetic aging is missing. Synthesizing evidence of interventions on epigenetic aging that can be adopted by a wider population is key to guide healthy aging initiatives and to reduce the burden of NCDs and CMDs. This scoping review will identify and assess non-pharmaceutical interventions aimed to slow down epigenetic aging, including their intervention components, and the mode used for intervention delivery. METHODS AND ANALYSIS: This protocol will include single- and multicomponent intervention studies that target individuals ≥ 18 years of age and use epigenetic clocks as primary or secondary outcomes. Five electronic databases will be searched for studies between July 2011 until December 2023. The final search will include the search terms adults, non-pharmaceutical interventions, epigenetic aging and their respective synonyms. We will include randomized controlled trials, non-randomized controlled studies, cohort studies, and case-control studies. Additionally, the reference list of other reviews will be screened for relevant articles. Study selection is carried out based on the defined eligibility criteria by two authors. Quality and risk of bias for the included studies will be assessed using the Critical Appraisal Skills Programme (CASP) checklist. Data extraction will include generic key information such as the research question and results, the intervention components, and specific epigenetic outcome measures used. Further data regarding the delivery mode of the treatment protocol will be collected. ETHICS AND DISSEMINATION: This scoping review will summarize the characteristics of non-pharmaceutical intervention studies on epigenetic aging. This review will be the first step to formally identify key intervention components and delivery modes to guide future research on healthy aging interventions. The results will be disseminated through a peer-reviewed publication and presented at relevant conferences. This review will synthesize information from available publications and does not require further ethical approval. REGISTRATION DETAILS: Open Science Framework https://doi.org/10.17605/OSF.IO/FEHNB.

Indexed as

AgingEpigenesis, GeneticAdultHumansResearch DesignScoping Reviews as Topic

Identifiers

PMID39159141
PMCPMC11332928

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.